P: Prevent deterioration

P: Prevent deterioration


Evidence
level


I


I


I


II


I


REDUCING RISK FACTORS for COPD is a priority, and smoking is the most important of these. A systematic review of 47 studies with an average follow-up of 11 years found a significantly higher decline in FEV1 in people who continued to smoke compared to those who ceased (Lee 2010) [evidence level 1]. The annual decline in FEV1 for those who stopped at the beginning of follow-up was 12.4 ml/yr (95%CI 10.1 to 14.7) and for those who stopped during the period of follow-up 8.5 ml/yr (95% CI 5.6 to 11.4), both less than people who continued to smoke. While there were limitations to the data, the review clearly found that in people who continue to smoke the annual decline in FEV1 is >10 ml/yr greater than in people who have never smoked or stopped smoking. Reduction of exposure to occupational dust, fumes and gases and to indoor and outdoor air pollutants is also recommended (Global Initiative for Chronic Obstructive Lung Disease 2016). Influenza immunisation reduces the risk of exacerbations and death [evidence level I], while long term oxygen therapy reduces mortality [evidence level I].